The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

However, there are certain things AI can't do -- and may never be able to do. One of them is to cure diseases. Biotech companies that develop and market breakthrough therapies for, thus far, ...

Legend Biotech Corp (NASDAQ:LEGN) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. In a board shakeup last month, Legend Biotech Corp (NASDAQ:LEGN) appointed chairman and executive ...